at Zacks.com (Jan 22, 2015)
Endo Health (ENDP) says the U.S. District Court has ruled against its bid to stop sales of generic versions of its painkiller Opana ER, saying the FDA has not unduly delayed making a determination on the matter as to whether the original formulation was withdrawn from the market for reasons of safety. The ruling now allows for a generic non-tamper resistant version to enter the market in January, 2013. Shares -3.6% AH.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 21, 2015)
at Zacks.com (Jan 15, 2015)
at Zacks.com (Jan 14, 2015)
at Zacks.com (Dec 31, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs